Oncolytics Q2 Loss Widens to $9.4M; Cash Drops to $4.1M, Going Concern Warning Reiterated

summarizeSummary

Oncolytics Biotech reported a wider Q2 loss and dwindling cash, reiterating going concern doubts while aggressively selling shares through a new ATM facility to stay funded.

check_boxKey Events · Earnings and Guidance · ONCY

• Q2 Net Loss Widens

  Net loss for Q2 2026 was $9.44 million, up from $5.28 million in Q2 2025, driven by higher R&D and G&A expenses.

• Cash Position Deteriorates

  Cash and cash equivalents fell to $4.12 million as of June 30, 2026, from $5.20 million at year-end 2025.

• Going Concern Warning Reiterated

  Management states existing cash, even with ATM proceeds, is not sufficient to fund operations for at least twelve months, raising substantial doubt about the company's ability to continue as a going concern.

• New ATM Facility and Dilution

  Entered into a $75 million Open Market Sale Agreement with Jefferies on April 6, 2026; sold 7.86 million shares for $7.15 million gross proceeds in Q2, and 2.32 million shares for $1.89 million after quarter-end.

auto_awesomeAnalysis · ONCY · Life Sciences

Oncolytics Biotech's Q2 2026 results show a net loss of $9.44 million, nearly double the prior-year quarter, while cash fell to $4.12 million. The company reiterates substantial doubt about its ability to continue as a going concern, with cash insufficient to fund operations for twelve months. To bridge the gap, it sold 7.86 million shares under a new $75 million ATM facility with Jefferies, raising $7.15 million in gross proceeds, and sold an additional 2.32 million shares after quarter-end. The stock trades at $0.81, below the $1.00 Nasdaq minimum, adding delisting risk to the liquidity crunch.